Inventiva S.A.

Stage 4 · Declining · week 4

As of Oct 22, 2026, Inventiva is in Stage 4, the downtrend phase, now in week 4 (since Sep 29, 2026). It closed at $3.60, 49.7% below its 52-week high and below its 200-day average, which is falling.

$3.60

-3.23% today

$850M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is IVA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 34w

S2 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 2w → S4 5w → S1 6w → S2 12w → S3 4w → S4 34w → S1 11w → S4 6w → S1 2w → S2 17w → S3 5w → S2 13w → S3 9w → S2 12w → S3 7w → S4 12w → S1 5w → S4 3w current

Total tracked: 165 weeks across 18 stage runs.

IVA among Biotechnology285th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…285	IVAInventiva S.A.	Stage 4 · wk 4	33	+4.3%

vs 52W High

-49.7%

$2.87 lo$7.15 hi

49.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-27.0%

200 DMA: $4.93 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.18x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+4.3%

-19.3%

-30.9%

YTD

-24.4%

-30.6%

Scan Membership

Breakout Watch

Latest: 2025-03-13

5 appearances in last 60 days. First seen: 2021-06-02.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 4 · Vol 1.18x

2026-10-21S4

Wk 4 · Vol 2.67x

2026-10-20S4

Wk 4 · Vol 1.39x

2026-10-19S4

Wk 3 · Vol 2.16x

2026-10-16S4

Wk 3 · Vol 2.79x

2026-10-15S4

Wk 3 · Vol 1.71x

2026-10-14S4

Wk 3 · Vol 1.90x

2026-10-13S4

Wk 3 · Vol 1.54x

2026-10-12S4

Wk 2 · Vol 2.06x

2026-10-09S4

Wk 2 · Vol 1.80x

2026-10-08S4

Wk 2 · Vol 1.42x

2026-10-07S4

Wk 2 · Vol 1.61x

Moving averages & range

50 DMA

$3.94

200 DMA

$4.93

52W High

$7.15

52W Low

$2.87

5D Low

$2.94

Resistance levels (recent highs)

20d High

$3.72

60d High

$4.90

120d High

$5.80

250d High

$7.15

Next resistance

+3.3%

to 20d High

ROE

-989.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 12.8

Inventiva: quick answers

What stage is Inventiva in?

As of Oct 22, 2026, Inventiva (IVA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 29, 2026 and is in week 4. What the four stages mean

Is Inventiva in an uptrend?

No. Inventiva is in a Stage 4 downtrend. It trades 27.0% below its 200-day average, which is falling.

How far is Inventiva from its 52-week high?

Inventiva closed at $3.60 on Oct 22, 2026, 49.7% below its 52-week high of $7.15. Its 52-week low is $2.87.

How has Inventiva performed over the past year?

As of Oct 22, 2026, Inventiva is down 30.6% over the past year and down 24.4% so far in 2026.

Which sector and industry is Inventiva in?

Inventiva is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.